Quimioterapia individualizada ou modificada (com ajuste de dose ou adiada)

Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A.

Fonte‎: Leuk Res 2011;35(8):991-7.

Indexado‎: PubMed 21474179

DOI‎: 10.1016/j.leukres.2011.02.021

https://www.ncbi.nlm.nih.gov/pubmed/21474179 (abre nova janela)

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. (abre nova janela)

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.

Fonte‎: Br J Haematol 2014;165(4):497-503.

Indexado‎: PubMed 24528179

DOI‎: 10.1111/bjh.12775

https://www.ncbi.nlm.nih.gov/pubmed/24528179 (abre nova janela)

Low-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses. (abre nova janela)

Dainer PM, Knupp CL, Sartiano GP.

Fonte‎: Am J Hematol 1992;40(2):156-7.

Indexado‎: PubMed 1585917

https://www.ncbi.nlm.nih.gov/pubmed/1585917 (abre nova janela)

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. (abre nova janela)

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

Fonte‎: Lancet Oncol 2013;14(6):525-33.

Indexado‎: PubMed 23578722

DOI‎: 10.1016/S1470-2045(13)70122-0

https://www.ncbi.nlm.nih.gov/pubmed/23578722 (abre nova janela)

Azacitidine and venetoclax in previously untreated acute myeloid leukemia. (abre nova janela)

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW

Fonte‎: N Engl J Med 2020;383(7):617-29.

Indexado‎: PubMed 32786187

DOI‎: 10.1056/NEJMoa2012971

https://www.ncbi.nlm.nih.gov/pubmed/32786187 (abre nova janela)

Treatment of acute leukaemia in adult Jehovah's Witnesses. (abre nova janela)

El Chaer F, Ballen KK

Fonte‎: Br J Haematol 2020;190(5):696-707.

Indexado‎: PubMed 31693175

DOI‎: 10.1111/bjh.16284

https://www.ncbi.nlm.nih.gov/pubmed/31693175 (abre nova janela)

Minimally-myelosuppressive asparaginase-containing induction regimen for treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS acute myeloid leukemia. (abre nova janela)

Emadi A, Bade NA, Stevenson B, Singh Z.

Fonte‎: Pharmaceuticals (Basel) 2016;9(1):E12.

Indexado‎: PubMed 27064021

DOI‎: 10.3390/ph9010012

https://www.ncbi.nlm.nih.gov/pubmed/27064021 (abre nova janela)

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (abre nova janela)

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.

Fonte‎: J Clin Oncol 2009;27(28):4733-40.

Indexado‎: PubMed 19720927

DOI‎: 10.1200/JCO.2008.19.8721

https://www.ncbi.nlm.nih.gov/pubmed/19720927 (abre nova janela)

Successful treatment of a Jehovah's Witness with acute promyelocytic leukemia. (abre nova janela)

Fujita H, Maruta A, Koharazawa H, Hattori M, Tomit N, Kodama F, Mohri H, Okubo T.

Fonte‎: Int J Hematol 1997;65(4):415-6.

Indexado‎: PubMed 9195782

https://www.ncbi.nlm.nih.gov/pubmed/9195782 (abre nova janela)

Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. (abre nova janela)

Garelius H, Grund S, Stockelberg D.

Fonte‎: Clin Case Rep 2015;3(5):287-90.

Indexado‎: PubMed 25984306

https://www.ncbi.nlm.nih.gov/pubmed/25984306 (abre nova janela)

Immediate or delayed therapy with 2-CdA for hairy cell leukemia in Jehova's Witness? (abre nova janela)

Juliusson G.

Fonte‎: Am J Hematol 1996;53(1):49.

Indexado‎: PubMed 8813099

DOI‎: 10.1002/(SICI)1096-8652(199609)53:1<49::AID-AJH12>3.0.CO;2-Z

https://www.ncbi.nlm.nih.gov/pubmed/8813099 (abre nova janela)

Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. (abre nova janela)

Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G.

Fonte‎: Eur J Haematol 2004;72(4):264-7.

Indexado‎: PubMed 15089764

DOI‎: 10.1111/j.0902-4441.2003.00211.x

https://www.ncbi.nlm.nih.gov/pubmed/15089764 (abre nova janela)

Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. (abre nova janela)

Lin CP, Huang MJ, Liu HJ, Chang IY, Tsai CH.

Fonte‎: Am J Hematol 1996;51(3):251-2.

Indexado‎: PubMed 8619417

DOI‎: 10.1002/(SICI)1096-8652(199603)51:3<251::AID-AJH20>3.0.CO;2-I

https://www.ncbi.nlm.nih.gov/pubmed/8619417 (abre nova janela)

Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. (abre nova janela)

Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J.

Fonte‎: Hematol Oncol 2014;32(1):40-6.

Indexado‎: PubMed 23963734

DOI‎: 10.1002/hon.2076

https://www.ncbi.nlm.nih.gov/pubmed/23963734 (abre nova janela)

Cytarabine dose for acute myeloid leukemia. (abre nova janela)

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

Fonte‎: N Engl J Med 2011;364(11):1027-36.

Indexado‎: PubMed 21410371

DOI‎: 10.1056/NEJMoa1010222

https://www.ncbi.nlm.nih.gov/pubmed/21410371 (abre nova janela)

Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. (abre nova janela)

Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L, Pricolo G.

Fonte‎: Bone Marrow Transplant 2003;32(4):433-6.

Indexado‎: PubMed 12900781

DOI‎: 10.1038/sj.bmt.1704179

https://www.ncbi.nlm.nih.gov/pubmed/12900781 (abre nova janela)

Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. (abre nova janela)

Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, Döhner H

Fonte‎: N Engl J Med. 2022;386(16):1519-31.

Indexado‎: PubMed 35443108

DOI‎: 10.1056/NEJMoa2117344

https://pubmed.ncbi.nlm.nih.gov/35443108/ (abre nova janela)

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. (abre nova janela)

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R.

Fonte‎: Gynecol Oncol 2012;124(2):221-4.

Indexado‎: PubMed 22055764

DOI‎: 10.1016/j.ygyno.2011.10.003

https://www.ncbi.nlm.nih.gov/pubmed/22055764 (abre nova janela)

The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products. (abre nova janela)

Nguyen N, Madarang E, Alencar A, Watts J, Bradley T

Fonte‎: Leuk Res Rep. 2022 25;18:100355.

Indexado‎: PubMed 36338830

DOI‎: 10.1016/j.lrr.2022.100355

https://pubmed.ncbi.nlm.nih.gov/36338830/ (abre nova janela)

Developing a blood conservation care plan for Jehovah's Witness patients with malignant disease. (abre nova janela)

Norfolk DR, Wade P, Carter R.

Fonte‎: Presented at the British Society for Haematology 47th Annual Scientific Meeting, Bournemouth [UK] April 2007.

https://www.transfusionguidelines.org/document-library/documents/developing-a-blood-conservation-care-plan-for-jehovah-s-witness-patients-with-malignant-disease/download-file/bbt-JW-Care-Plan-Malignant-Disease-2012.pdf (abre nova janela)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (abre nova janela)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Fonte‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indexado‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (abre nova janela)

Hematopoietic growth factors: personalization of risks and benefits. (abre nova janela)

Puhalla S, Bhattacharya S, Davidson NE.

Fonte‎: Mol Oncol 2012;6(2):237-41.

Indexado‎: PubMed 22497867

DOI‎: 10.1016/j.molonc.2012.03.001

https://www.ncbi.nlm.nih.gov/pubmed/22497867 (abre nova janela)

Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. (abre nova janela)

Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR

Fonte‎: Leuk Lymphoma 2021;62(6):1497-501.

Indexado‎: PubMed 33535838

DOI‎: 10.1080/10428194.2021.1876868

https://www.ncbi.nlm.nih.gov/pubmed/33535838 (abre nova janela)

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. (abre nova janela)

Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM

Fonte‎: Blood 2020;135(7):463-71.

Indexado‎: PubMed 31841594

DOI‎: 10.1182/blood.2019002140

https://www.ncbi.nlm.nih.gov/pubmed/31841594 (abre nova janela)

Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. (abre nova janela)

Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarín-Arzaga LD, Manzano C.

Fonte‎: Bone Marrow Transplant 2005;36(8):715-20.

Indexado‎: PubMed 16113672

DOI‎: 10.1038/sj.bmt.1705126

https://www.ncbi.nlm.nih.gov/pubmed/16113672 (abre nova janela)

A Mexican way to cope with stem cell grafting. (abre nova janela)

Ruiz-Delgado GJ, Ruiz-Argüelles GJ.

Fonte‎: Hematology 2012;17 Suppl 1:S195-7.

Indexado‎: PubMed 22507819

DOI‎: 10.1179/102453312X13336169157130

https://www.ncbi.nlm.nih.gov/pubmed/22507819 (abre nova janela)

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (abre nova janela)

Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F.

Fonte‎: Blood 2009;113(9):1875-91.

Indexado‎: PubMed 18812465

DOI‎: 10.1182/blood-2008-04-150250

https://www.ncbi.nlm.nih.gov/pubmed/18812465 (abre nova janela)

SCT in Jehovah's Witnesses: the bloodless transplant. (abre nova janela)

Sloan JM, Ballen K.

Fonte‎: Bone Marrow Transplant 2008;41(10):837-44.

Indexado‎: PubMed 18246110

DOI‎: 10.1038/bmt.2008.5

https://www.ncbi.nlm.nih.gov/pubmed/18246110 (abre nova janela)

Treatment of acute myelogenous leukemia with outpatient azacitidine. (abre nova janela)

Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J.

Fonte‎: Cancer 2006;107(8):1839-43.

Indexado‎: PubMed 16967444

DOI‎: 10.1002/cncr.22204

https://www.ncbi.nlm.nih.gov/pubmed/16967444 (abre nova janela)

Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's Witness. (abre nova janela)

van Akkooi AC, Golab-Schwarz HD, Eggermont AM, van Geel AN.

Fonte‎: Eur J Cardiothorac Surg 2006;30(2):408-10.

Indexado‎: PubMed 16829108

DOI‎: 10.1016/j.ejcts.2006.04.020

https://www.ncbi.nlm.nih.gov/pubmed/16829108 (abre nova janela)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. (abre nova janela)

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Fonte‎: Onco Targets Ther 2013;7:13-21.

Indexado‎: PubMed 24368888

DOI‎: 10.2147/OTT.S53348

https://www.ncbi.nlm.nih.gov/pubmed/24368888 (abre nova janela)

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. (abre nova janela)

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.

Fonte‎: J Clin Oncol 2007;25(30):4722-9.

Indexado‎: PubMed 17947719

DOI‎: 10.1200/JCO.2007.12.2440

https://www.ncbi.nlm.nih.gov/pubmed/17947719 (abre nova janela)

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. (abre nova janela)

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P

Fonte‎: Blood 2020;135(24):2137-45.

Indexado‎: PubMed 32219442

DOI‎: 10.1182/blood.2020004856

https://www.ncbi.nlm.nih.gov/pubmed/32219442 (abre nova janela)